EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real‐World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated Before the Era of Anti‐ CD38 Antibodies: The EMMY Cohort From 2017 to 2020

Laure Vincent, Olivier Decaux, Aurore Perrot iD, Bruno Royer, Thomas Chalopin, Arthur Bobin, Margaret Macro, Denis Caillot, Lionel Karlin, Caroline Jacquet, Cécile Sonntag, Mohamad Mohty und 13 weitere

Cancer Medicine · 2025-03 · 14 (6)

DOI: 10.1002/cam4.70619 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 14.03.2025. Verfasst von Laure Vincent und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Hematology, Montpellier University Hospital Center, Montpellier, France. Hauptthemen laut MEDLINE: Multiple Myeloma, Antineoplastic Combined Chemotherapy Protocols, ADP-ribosyl Cyclase 1. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Oncology, Amgen, Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims/Background Recent agents have profoundly reshaped the multiple myeloma (MM) landscape. Their real‐world impacts need to be assessed over the long term.

Methods

EMMY is a non‐interventional, prospective dynamic cohort, conducted in France, since 2017, with 900 patients enrolled each year. Newly diagnosed MM (NDMM) who initiated a treatment from 2017 to 2020 are here described.

Results

A total of 1036 non‐transplant eligible (NTE) patients (median age: 74.9 years) and 561 patients who received autologous stem cell transplantation (ASCT) (median age: 60.6 years) were enrolled. For ASCT patients, a shift in induction treatment from bortezomib‐thalidomide‐dexamethasone (VTd) (29.1%) to bortezomib‐lenalidomide‐dexamethasone (VRd) (55.1%) marked the period. Maintenance treatment with R after ASCT became a standard (75% of patients). In NTE patients, R‐based regimens were increasingly used from 29.4% in 2017 (of whom Rd.: 17.0%, VRd: 10.6%) to 73.3% in 2020 (of whom Rd.: 21.8%, VRd: 48.5%). Median progression‐free survival (mPFS) was 46.5 months (95% CI: 37.8–50.6) and 18.7 months (95% CI: 16.3–20.8) in ASCT and NTE patients, respectively. In the ASCT group, patients treated with and without R maintenance had a mPFS of 51.8 (95% CI: 44.1–NA) and 29.6 months (95% CI: 21.8–40.9), respectively. In the NTE group, the mPFS was 26.3 (95% CI: 21.9–30.9) and 14.6 months (95% CI: 11.9–17.7) in patients who received an R‐based and non‐R‐based regimen, respectively. The estimated 48‐month overall survival rates were 89% (95% CI: 84.5–92.2) and 63% (95% CI: 58.5–67.1) for ASCT and NTE patients, respectively.

Conclusions

The 2017–2020 period was marked by the expansion of R use in both NDMM ASCT and NTE patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaAntineoplastic Combined Chemotherapy ProtocolsADP-ribosyl Cyclase 1HumansMaleFemaleAgedMiddle AgedDexamethasoneProspective StudiesBortezomibTransplantation, AutologousFranceLenalidomideAged, 80 and overHematopoietic Stem Cell TransplantationTreatment OutcomeProgression-Free Survival

Stichwörter der Autor:innen

ASCT patientsNTE patientsfirst‐line therapymultiple myelomareal world

Substanzen

DexamethasoneBortezomibADP-ribosyl Cyclase 1Lenalidomide

Autor:innen und Institutionen

  • Department of Clinical Hematology, Montpellier University Hospital Center, Montpellier, France.
  • Centre Hospitalier Universitaire de Rennes - Hôpital Pontchaillou, Rennes, France.
  • Centre Hospitalier Universitaire de Toulouse, IUCT-Oncopole, Université de Toulouse, UPS, Service d'Hématologie, Toulouse, France.
  • Saint Louis Hospital, Paris, France.
  • Centre hospitalier universitaire de Tours, Hospital, Tours, France.
  • CHU Poitiers, Poitiers, France.

ORCID-Profile: Aurore Perrot, Philippe Moreau, Nathalie Texier, Cyrille Hulin

Förderung

  • Takeda Oncology
  • Amgen
  • Pfizer
  • Bristol Myers Squibb Foundation
  • Janssen-Cilag
  • GSK
  • Sanofi
  • GlaxoSmithKline foundation

Zitieren

APA

Vincent, L., Decaux, O., Perrot, A., Royer, B., Chalopin, T., Bobin, A., Macro, M., Caillot, D., Karlin, L., Jacquet, C., Sonntag, C., Mohty, M., Frenzel, L., Jaccard, A., Manier, S., Sanhes, L., Chaoui, D., Moreau, P., Garlantézec, R., …, & Merzoug, K. B. (2025). Real‐World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated Before the Era of Anti‐ CD38 Antibodies: The EMMY Cohort From 2017 to 2020. Cancer Medicine, 14(6). https://doi.org/10.1002/cam4.70619

Vancouver

Vincent L, Decaux O, Perrot A, Royer B, Chalopin T, Bobin A, et al. Real‐World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated Before the Era of Anti‐ CD38 Antibodies: The EMMY Cohort From 2017 to 2020. Cancer Medicine. 2025;14(6). doi:10.1002/cam4.70619

BibTeX
@article{Vincent2025,
  author = {Vincent, Laure and Decaux, Olivier and Perrot, Aurore and Royer, Bruno and Chalopin, Thomas and Bobin, Arthur and Macro, Margaret and Caillot, Denis and Karlin, Lionel and Jacquet, Caroline and Sonntag, Cécile and Mohty, Mohamad and Frenzel, Laurent and Jaccard, Arnaud and Manier, Salomon and Sanhes, Laurence and Chaoui, Driss and Moreau, Philippe and Garlantézec, Ronan and Texier, Nathalie and Louni, Chanaz and Maarouf, Zakaria and Loiseau, Herve Avet and Hulin, Cyrille and Merzoug, Karim Belhadj},
  title = {Real‐World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated Before the Era of Anti‐ CD38 Antibodies: The EMMY Cohort From 2017 to 2020},
  journal = {Cancer Medicine},
  year = {2025},
  volume = {14},
  number = {6},
  doi = {10.1002/cam4.70619}
}
Kostenlos starten →